by Jon Fleetwood, Jon Fleetwood:
Hydrogel forms a “depot” under the skin, slowly releasing vaccine components for weeks.
Researchers at Stanford University, funded by the Bill & Melinda Gates Foundation with lab infrastructure funded by the U.S. National Institutes of Health (NIH), have developed an injectable hydrogel vaccine platform designed to remain in the body and slowly release vaccine components for weeks, including formulations tested using H5N1 avian influenza (“bird flu”) antigens.
TRUTH LIVES on at https://sgtreport.tv/
The move comes amid state-level, national, and international bird flu pandemic orchestration.
The technology relies in part on Pluronic F-127 (poloxamer 407), a polymer capable of forming a gel deposit after injection.
Scientific literature examining this same polymer shows that when it was used as a delivery medium in animal experiments, it dramatically increased the lethality of inflammatory toxins—reducing the lethal dose (LD50) of bacterial endotoxin in mice by roughly 10–15-fold, meaning animals were far more likely to die from the toxin when the polymer was present (see more on this below).
The hydrogel vaccine platform is described in the study “Enabling Global Access to Potent Subunit Vaccines with a Simple and Scalable Injectable Hydrogel Platform,” published in January in the Royal Society of Chemistry’s peer-reviewed journal Biomaterials Science.
The work was led by Eric A. Appel, a materials scientist at Stanford University, along with collaborators across multiple Stanford biomedical research programs.
According to the paper, the system forms a hydrogel depot in tissue after injection, allowing vaccine components to remain localized and be released gradually over time.
The authors wrote that the hydrogel platform can “prolong release of subunit vaccine cargo over a period of weeks.”
The experimental system was tested using the purported hemagglutinin protein from the H5N1 influenza virus, the viral surface protein commonly targeted in bird-flu vaccine research.
Organizations Involved
The hydrogel vaccine technology was developed at Stanford University with financial support and laboratory infrastructure from multiple sources.
Research Institution
- Stanford University
Funding and Research Support Acknowledged in the Study
- Bill & Melinda Gates Foundation
- U.S. National Institutes of Health (NIH), which supported laboratory research infrastructure through Shared Instrumentation Grant 1S10OD026831-01
The Gates Foundation provided funding supporting the development of the vaccine platform itself.
The NIH grant cited in the research funded a shared laboratory instrument used during the experiments—a high-parameter flow cytometer located in Stanford’s Shared FACS Facility.
Polymer Hydrogel Carrier
The injectable gel used in the platform is built from Pluronic F-127 (poloxamer 407), a synthetic polymer designed to form a semi-solid depot inside the body after injection.
Scientific research examining this same polymer has found that it can dramatically intensify inflammatory toxicity in animal experiments.
In one study published in Critical Care Medicine, researchers delivered bacterial endotoxin (lipopolysaccharide, or LPS) to mice using Pluronic F-127 instead of saline.
The results showed that the amount of toxin required to kill half the animals dropped 10–15-fold when the polymer was present.
Read More @ jonfleetwood.substack.com
